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Abstract. The role of aggregate formation in the pathophysiology of Huntington’s disease (HD) remains uncertain. However,
the temporal appearance of aggregates tends to correlate with the onset of symptoms and the numbers of neuropil aggregates
correlate with the progression of clinical disease. Using highly sensitive immunohistochemical methods we have detected
the appearance of diffuse aggregates during embryonic development in the R6/2 and YAC128 mouse models of HD. These
are initially seen in developing axonal tracts and appear to spread throughout the cerebrum in the early neonate.
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Huntington’s disease is a devastating autosomal
dominant neurodegenerative disease caused by the
expansion of a CAG trinucleotide repeat, coding for
the amino acid glutamine, in the first exon of the
huntingtin gene (HTT) which encodes the huntingtin
protein (HTT) [1]. Expansions of 40 or more CAG
repeats invariably cause disease with the age of onset
correlating with the size of the repeat expansion and
a median age of onset in the mid-40s [2]. Interme-
diate expansions of 36 to 39 repeats show reduced
penetrance. There are currently no disease-modifying
treatments and FDA-approved medications provide
only symptomatic relief.
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The pathology of HD has been defined by the
pronounced degeneration of the striatum and cor-
tex, associated with the appearance of intranuclear
inclusions and neuropil aggregates comprised of
amyloid-like fragments derived from the N-terminal
region of mutant huntingtin (mHTT) and containing
the expanded polyglutamine segment [3]. Although
a correlation exists between the density of neu-
ropil aggregates in HD and the severity of clinical
pre-mortem symptoms [4], the exact role of these
aggregates in the pathophysiology of the disease
remains unclear. This uncertainty arises in part
from the study of animal models of HD where a
lack of correlation between the numbers of inclu-
sions and the symptoms of disease can be striking.
For example, the YAC128 mouse develops large
numbers of nuclear inclusions in addition to large
numbers of neuropil aggregates, while the similarly
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Fig. 1. A. S830 staining of R6/2 mouse brain at E17, P0, P5 and
P21 showing staining initially restricted to developing white matter
tracts and appearing extracellular. B. S830 (left) and Nissl (right)
staining of YAC128 at E17 and E19 showing preponderance of
S830 staining associated with developing white matter tracts and
fiber bundles. C. Enlargement of areas shown in B: S830 (left) and
Nissl (right) reveal inverse relationship between S830 and Nissl
staining, particularly in the developing external capsule and fiber
bundles in the developing striatum. D. Enlargement of a similar
region in P0 R6/2 mouse brain showing diffuse staining of corticos-
triatal fibers with weak staining of cortical dendrites (left); staining
of the same region in WT P0 brain (right) under identical condi-
tions reveals the total absence of immunoreactivity with S830.
E. High power view of external capsule of E17 R6/2 mouse brain
stained with S830 showing diffuse nature of staining and complete
absence of discrete mHTT aggregates; field size: 200 × 80.
symptomatic BACHD97 transgenic mice have con-
siderably smaller numbers of neuropil aggregates
and no intranuclear inclusions, Furthermore, behav-
ioral abnormalities have been found to precede the
appearance of conventional inclusions in a transgenic
rat model of HD [5]. Nevertheless, the presence of
inclusions in all animal models of HD, appearing
around the onset of symptoms of disease provides
compelling evidence for a central role of aggregation
and aggregate formation. In several diseases, collec-
tively termed protein aggregation disorders, it has
been proposed that neurotoxicity may be mediated
by oligomeric forms and that mature inclusions may
actually be protective; although evidence in some
experimental models of HD supports this concept
[6, 7], this does not exclude the possibility that some
subset of aggregates or intermediate in the aggrega-
tion process may play a pivotal role in the disease.
Moreover, numerous studies have reproduced many
of the pathological sequelae of HD by the exoge-
nous addition of aggregates of mutant huntingtin or
of synthetic polyglutamine aggregates leading to the
concept that these disorders may spread through the
brain in a prion-like manner [8, 9].
During an evaluation of the earliest stages of
inclusion pathology in the R6/2 mouse, a high den-
sity of staining with the aggregate-specific antibody,
S830 [10], was seen throughout the cerebral neu-
ropil particularly in younger (2-3 weeks) animals.
This polyclonal sheep antibody was raised against
a recombinant GST-exon 1 HTT fusion protein with
53Q and reacts in a highly selective and sensitive
manner with mHTT aggregates and in fixed tissue
is unreactive with mHTT or native huntingtin. The
use of a xenogeneic antibody permits the use of
highly sensitive indirect immunohistochemical meth-
ods which cannot be used for mouse monoclonal
antibodies such as mEM48 and the MW series due
to the invariable presence of background levels of
mouse IgG in mouse brain sections. To determine the
age of onset of this reactivity we examined brains
from E17 embryos and P0 and P5 pups. As shown
in Fig. 1A, dense diffuse staining of axon bundles
was seen at E17; at P0 mixed diffuse staining of
immature white matter and brain parenchyma was
seen. At P5 diffuse staining was limited to the neu-
ropil and by P21 the density of neuropil staining
was markedly reduced coincident with the onset of
formation of neuropil aggregates and the intranu-
clear accumulation of mHTT aggregates (Fig. 1A).
A strikingly similar diffuse staining of developing
white matter was seen with embryonic YAC128 mice
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Fig. 2. S830 staining of 7 week-old heterozygous (A, B) and homozygous (C, D) zQ175 mouse brain. In heterozygous Q175 mice, A and B,
minimal neuronal nuclear cellular staining was limited to the CA1 region, the parasubiculum (PaS) and deep layer V neurons in entorhinal
cortex (Ent, TeA), while diffuse staining (reduced or absent at later ages) was present in these regions and in the substantia nigra (SNR). At
7 weeks of age homozygous zQ175 mouse brain, C and D, showed exclusively neuronal nuclear staining, in CA1 region of dentate gyrus
(DG), in parasubiculum (PaS), and in cortex, with primary visual (V1), somatosensory (S1), temporal association (TeA), retrosplenial (RS)
and entorhinal (Ent) shown here.
(Fig. 1B), despite the relatively protracted prodromal
period prior to neurodegenerative pathology in this
model [11, 12].
In order to determine whether there was a corre-
lation between the level of persistent diffuse S830
reactivity and symptoms of disease we took advan-
tage of two models in which aggregate formation
had been reported to occur in the absence of sig-
nificant changes in motor function or behavior. The
asymptomatic ‘short-stop’ mouse expresses a trun-
catedexpandedHTTfragmentencodedbyexons1and
2 that had been reported to lead to a greater density
of mHTT inclusions than seen in the YAC128 [13].
We performed a quantitative analysis of the density
of the S830 reactivity between YAC128 and short-
stop sections from mice aged 6 months. We found
that there was a significant elevation in intercellular
S830 immunoreactivity in the YAC128 as compared
to the short-stop (arbitrary intensity units: 35.9 ± 9.7
and22.2 ± 5.6 respectively; t-test:p = 0.032).The res-
cue of the BACHD phenotype by the expression of
a human transgene encoding B-crystallin under the
GFAP promoter was recently described, in which the
total number of S830 positive neuropil aggregates was
reported to be unaffected by the presence of the trans-
gene, although the number of large aggregates was
significantly reduced [14]. When sections from mice
aged 12 months were analyzed for the density of extra-
cellular reactivity in cortex and striatum we found
that the double transgenics displayed a lower level
(arbitrary intensity units): 70.2 ± 2.6 vs. 82.3 ± 14.2
(t-test: p = 0.06) than in the BACHD mice.
A further example of diffuse aggregate staining
was seen in zQ175 heterozygous knock-in mice
(Fig. 2). At 7 weeks (the earliest age studied)
these mice exhibited diffuse S830 staining in several
regions, predominantly in those that first developed
mHTT inclusions at later ages. This staining was
essentially absent from zQ175 homozygous mice
which by this age already expressed widespread
neuronal intranuclear accumulations of mHTT and
numerous small neuropil aggregates.
We conclude that a novel form of mHTT aggre-
gate is generated in the brains of HD models during
embryonic development and that this persists for a
variable period of time in the post-natal mouse in
a diffuse form, distributed widely throughout the
cerebrum. These ‘proto-aggregates’ are the earliest
form of mHTT aggregate yet detected by immuno-
histochemical methods. The similarity in embryonic
distribution between the R6/2 and YAC128 is taken
to suggest that either the intact mHTT in the YAC128
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mouse is efficiently processed to an N-terminal
fragment or that an N-terminal mHTT fragment
is generated by incomplete splicing [15] or by
RAN translation [16]. Additionally, given accumulat-
ing evidence that HD includes neurodevelopmental
abnormalities [17–19], these observations support
a role for mHTT aggregation in the earliest stages
of the disease. Finally, recent studies have shown
that certain features of Huntington’s disease in the
adult BACHD mouse model were retained when
the expression of mutant protein was switched off
at weaning [20], confirming an important role for
expression of the mutant protein during develop-
ment. Confirmation of a role for proto-aggregates in
the pathophysiology of disease will add significantly
to our understanding of HD and potentially provide
novel targets for pharmacological intervention and
disease prevention.
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